Alivus Life Sciences: FY26 Revenue Rs. 25,518 Mn, PAT Rs. 5,645 Mn
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 14 May 2026, 08:00 PM IST · BSE ID: f4f25678-abfc-4625-97a5-af40f4895630
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its financial results for the full year and last quarter, showing growth in revenue and profit.
🤖 AI Summary
- Alivus Life Sciences reported FY26 revenue from operations of Rs. 25,518 Mn, a 6.9% YoY growth.
- FY26 Profit After Tax (PAT) stood at Rs. 5,645 Mn, showing 16.2% YoY growth.
- EBITDA for FY26 reached Rs. 8,577 Mn, growing 19.6% YoY with margins at 33.6%.
- Company generated free cash flow of Rs. 2,590 Mn during FY26, with cash of Rs. 7,824 Mn.
- Non-GPL business grew 13% and CDMO business grew 18% YoY in FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
FY26 Revenue from operations
Rs. 25,518 Mn
6.9%
Q4FY26 Revenue from operations
Rs. 6,891 Mn
6.1%
FY26 EBITDA
Rs. 8,577 Mn
19.6%
FY26 EBITDA margins
33.6%
360 bps YoY
FY26 PAT
Rs. 5,645 Mn
16.2%
FY26 PAT margins
22.1%
180 bps YoY
FY26 Free cash flow
Rs. 2,590 Mn
Cash and Cash Equivalents (Mar 31, 2026)
Rs. 7,824 Mn
🏢 How This Affects the Company
The company's non-GPL business grew 13% and CDMO business grew 18% YoY, indicating diversification and strength in contract development and manufacturing services. New R&D center in Taloja for complex chemistry and oncology research supports future product pipeline.
FY26 revenue from operations increased by 6.9% YoY to Rs. 25,518 Mn, and PAT grew 16.2% YoY to Rs. 5,645 Mn, reflecting improved profitability. EBITDA margins expanded to 33.6%, up 360 bps YoY, driven by favorable product mix and controlled expenses. Strong free cash flow of Rs. 2,590 Mn enhances financial flexibility.
Commencement of construction for a new R&D facility in Taloja admeasuring 10,000 square meters will expand capabilities in flow chemistry, complex products, and green chemistry. Progress on Solapur Phase 1 and 1.1 construction for 465 KL capacity indicates ongoing manufacturing expansion.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should note the financial results and dividend declaration for FY26.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed a 16.2% YoY increase in FY26 profit for the year to Rs. 5,644.83 Million. Shareholders on record for the dividend declaration will receive Rs. 5/- per share.
🔍
Management Signal
Management indicates a focus on sustainable growth, operational performance improvement, and strategic investments in R&D and manufacturing capacity.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor for sustained high single-digit revenue growth and margins above 30%.
Updates on Solapur Phase 1 and 1.1 construction progress for 465 KL capacity.
Progress on Taloja R&D centre construction and expansion into complex chemistry research.
LOW RISK
The filing indicates strong financial performance and strategic growth initiatives.
💡 Investor Takeaway
Alivus Life Sciences reported FY26 revenue from operations of Rs. 25,518 Mn (up 6.9% YoY) and PAT of Rs. 5,645 Mn (up 16.2% YoY). EBITDA margins expanded to 33.6% for FY26. The company also confirmed a dividend of Rs. 5/- per share for FY26 in a concurrent filing.
⚖️ Strengths & Concerns
✅ Positives
- FY26 PAT grew 16.2% YoY to Rs. 5,645 Mn with PAT margins at 22.1%, up 180 bps YoY, demonstrating enhanced profitability.
- EBITDA margins for FY26 were 33.6%, up 360 bps YoY, driven by improved operating performance and disciplined expense control.
⚠️ Concerns
- The GPL business segment de-grew by 4.9% during FY26, indicating a decline in a specific product area.
- The press release does not detail specific revenue contributions from key geographies mentioned (India, Europe, ROW, Japan, LATAM).
📅 Company Track Record
A concurrent filing on May 14, 2026, disclosed Audited Financial Results for FY26, reporting Profit for Year up 16.24% to Rs. 5,644.83 Million and a dividend of Rs. 5/- per share. This press release provides further details on the financial performance, aligning with previously reported figures.
Based on publicly available historical data. For context only.